Sparsentan functions and effects

Sparsentanis a receptor for endothelinA type receptor (ETAr) and angiotensin ⅱ1 type receptor (AT1r). Sparsentan is a new drug approved by the U.S. Food and Drug Administration in February 2023 to reduce the risk of disease progression. span>Primary ImmunoglobulinANephropathy (IgAN) Urinary protein excretion (albuminuria) in adults. Currently, sparsentan is the only approved drug in a new class of drugs called dual endothelin angiotensin receptor antagonists (DEARAs), which are the first non-immunosuppressive treatments to reduce IgAN proteinuria (also known as Berger disease) proteinuria. This once-daily oral medication works by selectively targeting IgA-1 and angiotensin II, two key pathways in kidney disease progression.

The approval was supported in a new Phase IIIPROTECT study comparing 404 in adult patients with IgA nephropathy and persistent proteinuria taking 400mg sparsentan and 300 mg irbesartan, even with angiotensin-converting enzyme (ACE) therapy or angiotensin receptor blockers (ARBs). After 36weeks, patients receiving sparsentan had an average 50%reduction in proteinuria from baseline in the new label or window, while those receiving irbes The number of patients treated with artan dropped by 15%, meeting the trial's primary endpoint (P<0.0001). If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.